ADARx Pharmaceuticals $1.74B US IPO
Analysis based on 6 articles · First reported Sep 21, 2026 · Last updated Sep 21, 2026
The listing signals continued investor appetite for later-stage biotech assets and provides a valuation benchmark for the RNA therapeutics space, potentially encouraging further biotech IPO filings. AbbVie's anchor investment offers external validation of ADARx's platform, though elevated Treasury yields and interest rates keep the broader IPO window selective and could pressure pricing.
ADARx Pharmaceuticals, a San Diego-based developer of RNA-based drugs for rare immune, kidney, cardiovascular and neurological diseases, announced on September 21, 2026 that it is seeking a valuation of up to $1.74 billion in its US initial public offering. The company aims to raise up to $371.9 million by offering 21.9 million shares priced between $15 and $17 each, and plans to list on Nasdaq under the symbol ADRX. AbbVie has agreed to invest up to $100 million in a concurrent private placement that would give it a roughly 4.9% stake in ADARx following the IPO; AbbVie had previously paid ADARx $335 million in May 2025 for a research collaboration. The offering is underwritten by JPMorgan, Morgan Stanley, Toronto-Dominion Bank — TD Cowen, UBS Investment Bank and LifeSci Capital. The IPO comes amid a selective reopening of the biotech listing market, with peers Retension Pharmaceuticals and TRex Bio filing for listings and Bicara Therapeutics debuting after raising $350 million in an upsized IPO, even as elevated Treasury yields and higher interest rates have pushed some prospective issuers to the sidelines. ADARx's most advanced candidate, onvuzosiran, is in late-stage testing for hereditary angioedema, with three programs in clinical testing and two in advanced preclinical development.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard